Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. ##STR00001##

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. ##STR00001##

The invention provides new heterocyclic compounds having the general formula (I)

##STR00001##

wherein A, L, X, m, n, R.sup.1, R.sup.2 and R.sup.3 are as described herein, pharmaceutically acceptable salts thereof, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Bis-amide inhibitors of SARS-CoV-2 (COVID), pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: ##STR00001##
wherein the variables are as defined herein.

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of formula I: ##STR00001##
wherein the variables are as defined herein.

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: ##STR00001##
wherein the variables are as defined herein.

An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.

An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.

A method for applying ultrasound to activate a cavitation enhancing agent in the presence of a therapeutic compound and a microbial biofilm is provided. The ultrasound energy causes the cavitation enhancing agent to cavitate in the ultrasound field. The cavitation of the resultant bubble causes fluid streaming and shear forces at and near the biofilm, causing enhanced penetration of the therapeutic compound into the biofilm, and resulting in improved efficacy of the therapeutic compound against the biofilm. The method further includes cavitation enhancing agents which can be loaded with oxygen gas or combined with microbubbles which carry oxygen gas, which further potentiate antibiotic efficacy against the biofilm.